Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

Aptar launches digital disease management platform
Aptar launches digital disease management platform

Aptar Pharma has added another element to its suite of digital support tools for patients as they make their journey through the healthcare system.

Eligo Bioscience’s EB300 Gains Orphan Drug and Rare Pediatric Disease Designations
Eligo Bioscience’s EB300 Gains Orphan Drug and Rare Pediatric Disease Designations
The FDA has granted Eligo Bioscience Orphan Drug and Rare Pediatric Disease designations for its investigational gene therapy EB003 for treating patients with Shiga-toxin producing bacterial infec...
The new compound that destroys the MRSA superbug
The new compound that destroys the MRSA superbug
A compound that both inhibits the MRSA superbug and renders it more vulnerable to antibiotics has been discovered by scientists at the University of Bath led by Dr. Maisem Laabei and Dr. Ian Blagbr...
Gilead Sciences Gets Priority Review for New Trodelvy Indication
Gilead Sciences Gets Priority Review for New Trodelvy Indication
The FDA has accepted Gilead Sciences’ supplemental Biologics License Application (sBLA) of Trodelvy (sacituzumab govitecan-hziy) for Priority Review in treating patients with unresectable locall...
Nanoscope Therapeutics Gets Fast Track Designation for MCO-010
Nanoscope Therapeutics Gets Fast Track Designation for MCO-010
Nanoscope Therapeutics has received FDA’s Fast Track designation for its MCO-010, an investigational gene therapy for treatment of retinitis pigmentosa, a group of inherited diseases causing reti...
FDA Approves scPharmaceuticals’ Furoscix for Chronic Heart Failure Congestion
FDA Approves scPharmaceuticals’ Furoscix for Chronic Heart Failure Congestion
The FDA has approved scPharmaceuticals’ Furoscix (furosemide injection) for treatment of congestion due to fluid overload in adults with chronic heart failure. ...
AstraZeneca’s intranasal COVID vaccine fails first clinical test
AstraZeneca’s intranasal COVID vaccine fails first clinical test
An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immu...
FDA and C-Path Team Up over Rare Genetic Disease
FDA and C-Path Team Up over Rare Genetic Disease
The FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) are teaming up with the Critical Path Institute (C-Path) for a “pre-consortiumâ...
Theratechnologies’ Trogarzo Receives FDA Approval for 30-Second IV Push
Theratechnologies’ Trogarzo Receives FDA Approval for 30-Second IV Push

Montreal, Canada-based Theratechnologies has received FDA’s approval for Trogarzo (ibalizumab-uiyk) for administration by intravenous (IV) push.

FDA Approves Alnylam’s sNDA for Oxlumo in Advanced Primary Hyperoxaluria Type 1
FDA Approves Alnylam’s sNDA for Oxlumo in Advanced Primary Hyperoxaluria Type 1
The FDA has approved Alnylam Pharmaceuticals’ supplemental new drug application (sNDA) for Oxlumo (lumasiran) to treat primary hyperoxaluria type 1 by lowering plasma oxalate levels in adult and...
Kite Pharma Gets FDA OK for Retroviral Vector Manufacturing Facility
Kite Pharma Gets FDA OK for Retroviral Vector Manufacturing Facility

Gilead Sciences’ Kite Pharma has received FDA’s approval for its retroviral vector manufacturing facility in Oceanside, Calif.

FDA Approves Boostrix for Whooping Cough Prevention
FDA Approves Boostrix for Whooping Cough Prevention
The FDA has approved GlaxoSmithKline’s Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) vaccine for immunization during the third trimester of pregnancy to prevent pe...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand